Clinical Evaluation of a (1,3)-β- d -Glucan Assay for Presumptive Diagnosis of Pneumocystis jiroveci Pneumonia in Immunocompromised Patients | Zendy

Valerio Del Bono | Zendy; Alessandra Mularoni | Zendy; Elisa Furfaro | Zendy; Emanuele Delfino | Zendy; Lorenzo Rosasco | Zendy; Franca Miletich | Zendy; Claudio Viscoli | Zendy

Open Access

Clinical Evaluation of a (1,3)-β- d -Glucan Assay for Presumptive Diagnosis of Pneumocystis jiroveci Pneumonia in Immunocompromised Patients

Author(s) -

Valerio Del Bono,

Alessandra Mularoni,

Elisa Furfaro,

Emanuele Delfino,

Lorenzo Rosasco,

Franca Miletich,

Claudio Viscoli

Publication year - 2009

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00276-09

Subject(s) - pneumonia , pneumocystis pneumonia , echinocandins , microbiology and biotechnology , medicine , virology , immunology , pneumocystis jirovecii , biology , caspofungin , amphotericin b , antifungal

(1,3)-β-d -Glucan (BG) is a component of thePneumocystis jiroveci cell wall. Thirty-one immunocompromised patients with pneumonia (16 with presumptive pneumocystis pneumonia [PCP] and 15 with non-PCP) were evaluated for serum BG levels. Serum from all 16 presumptive PCP patients and from 2/15 patients with non-PCP was positive for BG. Results indicate that BG is a reliable marker for diagnosing PCP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research